Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer.

NCT00403429 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT00403429
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00403429 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study With Capecitabine as Monotherapy in the Treatment of Platinum Resistant or Refractory Ovarian Cancer.
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
July 31, 2008
Enrollment
36 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer